3 Lucrative Stocks Ideal for Long-Term Investment

Profitable Companies with a Competitive Advantage

Businesses that maintain strong operating margins often outperform their peers, as these margins provide the flexibility to reinvest in growth and secure a lasting position in the market. The most successful companies strike a balance between generating profits and reinvesting in their future, paving the way for enduring prosperity.

While not every profitable company deserves your attention, we’ve identified a select few that stand out for their potential. Here are three companies that utilize their robust financials to stay ahead of the competition.

Cal-Maine (CALM)

Latest 12-Month GAAP Operating Margin: 34.3%

Cal-Maine (NASDAQ:CALM), recognized for brands like Egg-Land’s Best and Land O’ Lakes, specializes in the production, packaging, and distribution of eggs.

What Makes CALM Noteworthy?

• Achieved impressive revenue growth of 18.5% over the past three years, reflecting its ability to expand its market presence.
• Strategic share repurchases in recent years have accelerated earnings per share growth, outpacing revenue increases.
• With a free cash flow margin of 22.5%, the company consistently reinvests or returns capital, and its expanding cash flow provides even more opportunities for future initiatives.

Currently priced at $89.32 per share, Cal-Maine trades at a forward P/E of 28.3. Curious if it’s a good time to invest?

JBT Marel (JBTM)

Latest 12-Month GAAP Operating Margin: 5%

JBT Marel (NYSE:JBT), whose roots date back to the invention of the mechanical milk bottle filler in 1884, develops and sells equipment for the food processing and aviation industries.

Why Does JBTM Stand Out?

• Exceptional annual revenue growth of 51.1% over the last two years has led to increased market share.
• Strong unit economics and a 34.9% gross margin allow for greater investment in marketing and research compared to competitors.
• Over the past two years, earnings per share have grown at an annual rate of 20.1%, surpassing industry peers.

JBT Marel is currently valued at $152.83 per share, with a forward P/E ratio of 18.7. Thinking about investing?

Medpace (MEDP)

Latest 12-Month GAAP Operating Margin: 21.1%

Founded in 1992, Medpace (NASDAQ:MEDP) offers outsourced clinical trial management and research services, supporting pharmaceutical, biotech, and medical device companies in developing new therapies.

Why Do We Favor MEDP?

• Consistent organic revenue growth averaging 15.9% over the past two years, highlighting its ability to expand without relying on acquisitions.
• Share buybacks over the last five years have fueled annual earnings per share growth of 31.7%, outpacing revenue growth.
• Free cash flow margin has increased by 6.4 percentage points in five years, giving Medpace more resources for growth, share repurchases, or dividends.

Medpace’s current share price of $469.51 reflects a forward P/E of 26.7. Wondering if now is the right time to buy?

Top Stocks for Any Market Environment

Don’t Miss: The Top 5 Momentum Stocks. The ideal moment to invest in a standout stock is when the market starts to recognize its potential. These companies aren’t just fundamentally strong—they’re also experiencing significant momentum right now, combining solid financials with timely growth.

Discover which stocks our AI-driven platform is highlighting this week. Check out the latest Strong Momentum stocks—absolutely free.

Past selections from our list include well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, as well as lesser-known companies such as Kadant, which delivered a 351% five-year return.